Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.
Also called NCT04488978
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 440 participants
- Sponsor
- Registry
-
NCT04488978
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04488978. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-21 (actual); primary completion 2021-11-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Irbesartan/Amlodipine
- Lead sponsor
- Handok Inc.
Record details
- Record id
cardio:ct-nct04488978- Content hash
9a8d3b2d8282397bab90316ccfcbe2d3f927fa73af08e9812361dac364b730a2